1. Home
  2. OLMA vs VIRT Comparison

OLMA vs VIRT Comparison

Compare OLMA & VIRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OLMA
  • VIRT
  • Stock Information
  • Founded
  • OLMA 2006
  • VIRT 2008
  • Country
  • OLMA United States
  • VIRT United States
  • Employees
  • OLMA N/A
  • VIRT N/A
  • Industry
  • OLMA Biotechnology: Pharmaceutical Preparations
  • VIRT Investment Bankers/Brokers/Service
  • Sector
  • OLMA Health Care
  • VIRT Finance
  • Exchange
  • OLMA Nasdaq
  • VIRT Nasdaq
  • Market Cap
  • OLMA 465.4M
  • VIRT N/A
  • IPO Year
  • OLMA 2020
  • VIRT 2015
  • Fundamental
  • Price
  • OLMA $6.10
  • VIRT $35.41
  • Analyst Decision
  • OLMA Strong Buy
  • VIRT Buy
  • Analyst Count
  • OLMA 5
  • VIRT 7
  • Target Price
  • OLMA $26.25
  • VIRT $29.50
  • AVG Volume (30 Days)
  • OLMA 1.2M
  • VIRT 947.9K
  • Earning Date
  • OLMA 11-12-2024
  • VIRT 01-23-2025
  • Dividend Yield
  • OLMA N/A
  • VIRT 2.71%
  • EPS Growth
  • OLMA N/A
  • VIRT 23.01
  • EPS
  • OLMA N/A
  • VIRT 1.98
  • Revenue
  • OLMA N/A
  • VIRT $1,910,017,000.00
  • Revenue This Year
  • OLMA N/A
  • VIRT N/A
  • Revenue Next Year
  • OLMA N/A
  • VIRT $2.12
  • P/E Ratio
  • OLMA N/A
  • VIRT $17.85
  • Revenue Growth
  • OLMA N/A
  • VIRT 10.60
  • 52 Week Low
  • OLMA $5.56
  • VIRT $16.02
  • 52 Week High
  • OLMA $16.78
  • VIRT $38.45
  • Technical
  • Relative Strength Index (RSI)
  • OLMA 27.05
  • VIRT 47.55
  • Support Level
  • OLMA $5.56
  • VIRT $36.13
  • Resistance Level
  • OLMA $6.87
  • VIRT $37.96
  • Average True Range (ATR)
  • OLMA 0.81
  • VIRT 1.03
  • MACD
  • OLMA -0.28
  • VIRT -0.37
  • Stochastic Oscillator
  • OLMA 10.12
  • VIRT 30.81

About OLMA Olema Pharmaceuticals Inc.

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Share on Social Networks: